Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.56 |
| ▸ | NPY1R | P25929 | 10/20 | 0.56 |
| ▸ | NPY2R | P49146 | 7/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373192 | 0.89 | NPBWR1 (0.63) | KISS1R | |
| SCHEMBL34464906 | 0.83 | NMUR2 (0.47) | NPY4RNPY5RNPY1RNPY2RKEAP1 | |
| SCHEMBL29871918 | 0.83 | NPY4R (0.66) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL18237095 | 0.83 | HDAC3 (0.49) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31430950 | 0.82 | NPY4R (0.54) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL28007642 | 0.81 | NPY4R (0.56) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL31026127 | 0.81 | NPY4R (0.57) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL24023999 | 0.80 | NPY4R (0.70) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL28007918 | 0.80 | NPY4R (0.57) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL29994317 | 0.80 | IL23R (0.52) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | NPY4R 39/4885NPY5R 92/4885NPY1R 22/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | NPY4R 39/4885NPY5R 92/4885NPY1R 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.